New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era by Jaime Rubio-Perez, Roberto Hernandez, Carlota Santolaya, Maria Cruz Martin-Soberon, Sandra Zazo, Nerea Carvajal, Federico Rojo

Get full text

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer by Ana Lameirinhas, Sandra Torres-Ruiz, Iris Garrido-Cano, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Sandra Zazo, Federico Rojo, Begoña Bermejo, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles

Get full text

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial by Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac

Get full text

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors by Anna Hernández‐Prat, Alejo Rodriguez‐Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí‐Llucià, Luis Soria‐Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere‐Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira, Joaquim Bellmunt

Get full text